Nicolette Senserrick joins as General Manager of Medical Relations, and Craig Thompson steps in as General Manager of Medical Sales.

The new hires follow significant developments for the company, including the introduction of same-day pharmacy delivery in Sydney through its Leafio brand and a new strategic distribution partnership with the IPA network.

Rhys Staley, Executive Director and Vice President at Montu, says he is excited about the new appointments.

“These new appointments reflect our intention to continue leading from the front throughout 2025.

“Moreover, they further our dedication to shaping the future of medical cannabis in Australia,” he says.

GM of Medical Sales, Mr Thompson, who brings 7 years’ experience working within the medicinal cannabis industry, says he is looking forward to being part of a dynamic and innovative home-grown business.

“Montu has consistently stood out to me as a key player in driving growth and change within the medicinal cannabis industry,” says Mr Thompson.

He aims to ensure the field team is well-equipped for success in their healthcare practitioner relationships.

GM Medical Relations, Ms Senserrick joins from WooliesX B2B and Woolworths at Work where she led dynamic teams to push powerful products to market.

At Montu, Ms Senserrick will be responsible for engaging with practitioners who may be unfamiliar with treating patients with medicinal cannabis.

“I am beyond excited to join Montu to help Australian health practitioners better navigate the medicinal cannabis landscape and prescribe with greater confidence,” she says.

The post Montu expands leadership team strengthening commitment to patient outcomes appeared first on Retail Pharmacy.

Montu Managing Director Christopher Strauch founded the company with the mission to provide patients with an alternative to conventional medication and help millions of people worldwide live better lives.

Mr Strauch says the company is proud to provide Australians with a “powerful alternative to traditional medications” and to “create a new standard in patient care”.

“Our ongoing growth is a result of our patient-centric approach and streamlined process, which gives patients access to a natural plant-based alternative to manage their chronic conditions in a fast and affordable way,” he said.

“Our key focus is to provide the best care and outcomes for our patients so they can experience the many benefits of medicinal cannabis when used and administered correctly.”

Conducting more than 50,000 patient consultations every year, Montu is making medicinal cannabis accessible and affordable to Australians with chronic medical conditions.

Consultations are conducted via the integrated telehealth platform, alternaleaf, with practitioners including registered nurses and qualified doctors.

The company’s clinical team provides patients with individualised care and alternative treatments for a range of chronic conditions, including chronic pain, anxiety, insomnia, and depression, to name a few.

Dr Parul Agarwal has been a doctor for the past 18 years and became an authorised medicinal cannabis prescriber two years ago after seeing a significant improvement in her patients with chronic pain.

“I started to prescribe medicinal cannabis as my patients were looking for natural remedies, especially cancer patients who needed help with chronic pain,” she said.

“I found that it worked beautifully for chronic pain, anxiety, depression, PTSD, ADHD and insomnia. I have seen how it has given my patients a better quality of life. I believe this is the beginning of how we perceive alternative medicine.”

For more information about Montu, visit: montu.com.au.

The post Medicinal cannabis company wins Deloitte’s Tech Fast 50 appeared first on Retail Pharmacy.